Polaprezinc (Zinc-L-Carnosine Complex) as an Add-on Therapy for Binge Eating Disorder and Bulimia Nervosa, and the Possible Involvement of Zinc Deficiency in These Conditions: A Pilot Study.
Adult
Antidepressive Agents
/ adverse effects
Binge-Eating Disorder
/ blood
Biomarkers
/ blood
Bulimia Nervosa
/ blood
Carnosine
/ adverse effects
Dietary Supplements
/ adverse effects
Drug Therapy, Combination
Feeding Behavior
/ drug effects
Female
Humans
Male
Middle Aged
Organometallic Compounds
/ adverse effects
Pilot Projects
Prospective Studies
Time Factors
Tokyo
Treatment Outcome
Young Adult
Zinc
/ blood
Zinc Compounds
/ adverse effects
Journal
Journal of clinical psychopharmacology
ISSN: 1533-712X
Titre abrégé: J Clin Psychopharmacol
Pays: United States
ID NLM: 8109496
Informations de publication
Date de publication:
Historique:
pubmed:
13
10
2020
medline:
27
7
2021
entrez:
12
10
2020
Statut:
ppublish
Résumé
Zinc plays an important role in appetite regulation. L-Carnosine, an endogenous dipeptide, may also regulate eating behavior via its histaminergic and antiglutamatergic properties. Polaprezinc (zinc-L-carnosine complex) is a medication for gastric ulcers. A small case series reported successful treatment of binge eating with add-on polaprezinc. This was an open trial of add-on polaprezinc in patients with binge eating disorder (BED; n = 22) or bulimia nervosa (BN; n = 7) receiving antidepressants. A 4-week baseline period was followed by a 16-week polaprezinc treatment at 150 mg/d (containing 34 mg zinc and 116 mg L-carnosine) in addition to ongoing psychotropic medications. We also assessed their zinc status via a laboratory index and zinc deficiency-related symptoms. At the study end, both conditions showed a significant reduction in the 4-week frequency of combined objective and subjective binge eating episodes, the 4-week frequency of days when at least 1 such episode occurred (only in BED), several aspects of eating disorder psychopathology (rated by the Eating Disorder Examination-Questionnaire), and comorbid depressive symptoms (rated by the 16-item Quick Inventory of Depressive Symptomatology [Self-Report]). Serum copper/zinc ratio decreased from 1.4 to 1.1 on average in both conditions. All patients had multiple zinc deficiency-related symptoms at baseline that substantially improved after polaprezinc treatment. Overall, the effectiveness of polaprezinc was greater in BED patients than in BN patients, with minor adverse effects. These findings offer preliminary evidence for the effectiveness of polaprezinc in treating BED and BN and suggest the involvement of zinc deficiency in these conditions.
Sections du résumé
BACKGROUND
BACKGROUND
Zinc plays an important role in appetite regulation. L-Carnosine, an endogenous dipeptide, may also regulate eating behavior via its histaminergic and antiglutamatergic properties. Polaprezinc (zinc-L-carnosine complex) is a medication for gastric ulcers. A small case series reported successful treatment of binge eating with add-on polaprezinc.
METHODS
METHODS
This was an open trial of add-on polaprezinc in patients with binge eating disorder (BED; n = 22) or bulimia nervosa (BN; n = 7) receiving antidepressants. A 4-week baseline period was followed by a 16-week polaprezinc treatment at 150 mg/d (containing 34 mg zinc and 116 mg L-carnosine) in addition to ongoing psychotropic medications. We also assessed their zinc status via a laboratory index and zinc deficiency-related symptoms.
RESULTS
RESULTS
At the study end, both conditions showed a significant reduction in the 4-week frequency of combined objective and subjective binge eating episodes, the 4-week frequency of days when at least 1 such episode occurred (only in BED), several aspects of eating disorder psychopathology (rated by the Eating Disorder Examination-Questionnaire), and comorbid depressive symptoms (rated by the 16-item Quick Inventory of Depressive Symptomatology [Self-Report]). Serum copper/zinc ratio decreased from 1.4 to 1.1 on average in both conditions. All patients had multiple zinc deficiency-related symptoms at baseline that substantially improved after polaprezinc treatment. Overall, the effectiveness of polaprezinc was greater in BED patients than in BN patients, with minor adverse effects.
CONCLUSIONS
CONCLUSIONS
These findings offer preliminary evidence for the effectiveness of polaprezinc in treating BED and BN and suggest the involvement of zinc deficiency in these conditions.
Identifiants
pubmed: 33044355
doi: 10.1097/JCP.0000000000001284
pmc: PMC7643788
pii: 00004714-202011000-00013
doi:
Substances chimiques
Antidepressive Agents
0
Biomarkers
0
Organometallic Compounds
0
Zinc Compounds
0
polaprezinc
0WA1B15A1Z
Carnosine
8HO6PVN24W
Zinc
J41CSQ7QDS
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
599-606Références
Int J Eat Disord. 1998 Jan;23(1):7-15
pubmed: 9429914
J Neurochem. 1999 Sep;73(3):1181-8
pubmed: 10461910
Pharmacol Rep. 2013;65(6):1558-71
pubmed: 24553004
Gen Hosp Psychiatry. 2008 Sep-Oct;30(5):471-5
pubmed: 18774432
Int J Eat Disord. 2011 Jan;44(1):81-90
pubmed: 21080416
Arch Gen Psychiatry. 2002 Aug;59(8):713-21
pubmed: 12150647
Front Pharmacol. 2017 Jun 30;8:414
pubmed: 28713269
Int J Eat Disord. 2017 Nov;50(11):1247-1254
pubmed: 28857236
Nutrition. 2008 Sep;24(9):827-31
pubmed: 18725079
Brain Res. 1993 Jun 4;613(1):88-95
pubmed: 7688643
Behav Res Ther. 2006 Jan;44(1):43-51
pubmed: 16301013
Arch Gen Psychiatry. 2000 Jul;57(7):659-65
pubmed: 10891036
Brain Res Bull. 2004 Mar 1;63(1):75-82
pubmed: 15121241
Nutrients. 2015 Jan 29;7(2):887-904
pubmed: 25642970
Biochemistry (Mosc). 2000 Jul;65(7):817-23
pubmed: 10951100
Pediatrics. 2017 Dec;140(6):
pubmed: 29122972
Neuropharmacology. 2011 Jul-Aug;61(1-2):228-33
pubmed: 21514311
J Abnorm Psychol. 2011 Feb;120(1):119-28
pubmed: 21171725
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Biol Psychiatry. 2003 Sep 1;54(5):573-83
pubmed: 12946886
J Clin Psychopharmacol. 2017 Dec;37(6):734-736
pubmed: 28926352
Neuropsychopharmacology. 2017 Jan;42(1):193-215
pubmed: 27629368
Eur Eat Disord Rev. 2014 Mar;22(2):140-6
pubmed: 24399652
Aging Dis. 2015 Oct 01;6(5):300-3
pubmed: 26425385
Neurosci Res. 2015 Mar;92:62-70
pubmed: 25450310
J Affect Disord. 2011 Oct;133(3):580-3
pubmed: 21621271
Biol Psychiatry. 2013 May 1;73(9):904-14
pubmed: 23290497
Prog Neurobiol. 2019 Apr;175:35-53
pubmed: 30593839
Ann Hematol. 2016 Apr;95(5):751-6
pubmed: 26931116
J Affect Disord. 1998 Sep;50(2-3):143-51
pubmed: 9858074
Front Endocrinol (Lausanne). 2013 Aug 15;4:103
pubmed: 23966982
Int J Eat Disord. 2010 Apr;43(3):195-204
pubmed: 20186717
Glia. 1998 Nov;24(3):346-51
pubmed: 9775986
Pharmacol Rep. 2015 Jun;67(3):659-62
pubmed: 25933983
Cochrane Database Syst Rev. 2003;(4):CD003391
pubmed: 14583971
Eur Eat Disord Rev. 2013 Jan;21(1):8-14
pubmed: 23059695
J Atten Disord. 2006 Feb;9(3):504-14
pubmed: 16481667
J Affect Disord. 2008 Dec;111(2-3):235-43
pubmed: 18405979
Int J Eat Disord. 2005 Mar;37(2):100-6
pubmed: 15732070
Int J Eat Disord. 2011 Sep;44(6):488-96
pubmed: 20872757
BMC Psychiatry. 2013 Nov 07;13:285
pubmed: 24200085
Nutrients. 2017 Nov 25;9(12):
pubmed: 29186856
Int J Eat Disord. 2003;34 Suppl:S30-8
pubmed: 12900984
Expert Rev Clin Pharmacol. 2018 Jan;11(1):95-108
pubmed: 28933969
Int J Eat Disord. 2008 Sep;41(6):520-6
pubmed: 18433015
Neuroscience. 2005;135(3):939-47
pubmed: 16125861
Int J Eat Disord. 2008 Nov;41(7):577-86
pubmed: 18473335
Physiol Rev. 2013 Oct;93(4):1803-45
pubmed: 24137022
J Clin Psychiatry. 1989 Dec;50(12):456-9
pubmed: 2600063
Neuroreport. 2010 Jul 14;21(10):704-8
pubmed: 20505551
Int J Eat Disord. 1997 Mar;21(2):115-27
pubmed: 9062835
J Nutr. 2000 May;130(5S Suppl):1493S-9S
pubmed: 10801965
Obes Res. 2005 Jun;13(6):1077-88
pubmed: 15976151
Nutrients. 2019 Aug 23;11(9):
pubmed: 31450770
J Trace Elem Med Biol. 2016 Jul;36:80-3
pubmed: 27259356
Pharmacol Biochem Behav. 2008 Jun;89(4):627-32
pubmed: 18377967
Biosci Biotechnol Biochem. 2018 Apr;82(4):683-688
pubmed: 29224504
Free Radic Biol Med. 2010 Mar 1;48(5):727-35
pubmed: 20043985